The first treatment to be offered for people with COVID-19 has proven to be of continued use in combating the disease.
New data on Veklury (remdesivir) in COVID-19 have been presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).
Findings from two studies provide insights on the use of Gilead Sciences' (Nasdaq: GILD) Veklury for people in and out of hospital with the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze